Description: RUA Life Sciences plc, together with its subsidiaries, engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates through Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments. The Biomaterials segment operates as depository of the Intellectual Property and licensing rights to a range of biostable and implantable polymers, including Elast-Eon and ECSil. The Contract Manufacture segment provides sub-contract manufacturing, assembly, packing and services to the medical device. The Vascular segment develops and commercializes bore polymer sealed grafts and soft tissue patches. The Structural Heart segment develops tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
Home Page: rualifesciences.com
2 Drummond Crescent
Irvine,
KA11 5AN
United Kingdom
Phone:
44 12 9431 7073
Officers
| Name | Title |
|---|---|
| Mr. William Donald Brown | Chief Executive |
| Mr. Lachlan Arthur Smith | CFO & Director |
| Kathryn Mary Full FCCA | Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 13.459 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8101 |
| Price-to-Sales TTM: | 3.867 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 40 |